Researchers in Uganda are set to introduce a second experimental Ebola vaccine to the neighboring Democratic Republic of Congo, where the virus has claimed more than 1,800 lives in the past year. The trial, supported by Doctors without Borders and the London School of Hygiene and Tropical Medicine, will be the largest yet conducted with this vaccine.
It is hoped the operation will provide key information about the immune response and the safety of the vaccine
180,000 people have received an experimental vaccine produced by Merck Pharmaceuticals. Although effective, the vaccine could not overcome impediments to virus containment in the country due to violence and resistance to health care interventions from communities that hadn’t experienced the disease. The new vaccine, produced by Janssen Pharmaceuticals, has been tested in about 6,000 people, with alot of them been Africans.
The trial is expected to last two years and will target 800 individuals, namely, health workers and front-line workers